medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2017, Number 01-02

<< Back Next >>

Medicina & Laboratorio 2017; 23 (01-02)

Performance of presepsin as early biomarker of sepsis in a high complexity hospital from Medellin, Colombia

Castaño-Sepúlveda TJ, Arévalo-Ruano ML, Castillo-Ramírez JA, Becerra-Argote MG, Ospina-Ospina S

Language: Spanish
References: 33
Page: 85-94
PDF size: 484.93 Kb.


ABSTRACT

Introduction: Presepsin is the soluble form of CD14 molecule, a glycoprotein expressed on the membrane surface of monocytes and macrophages and important to inflammatory response. Several studies suggest that presepsin measuring could be used as a good tool to early sepsis diagnosis. Objective: To determine the diagnostic and prognostic performance of presepsin in patients with clinical sepsis at a high complexity hospital from Medellin, Colombia. Materials and methods: A prospective, descriptive cohort study was performed in 60 patients diagnosed with clinical sepsis between March and December of 2012. Presepsin measurement was made at diagnosis time and after 24 and 72 hours. Blood culture, C-reactive protein and procalcitonin were also measured but only at the diagnosis time. Results: 98.3% of patients had presepsin values suggestive of sepsis, with a significantly higher value in patients without clinical improvement (greater than 700 pg/mL). Presepsin values greater than 1,000 pg /mL at 0 and 72 hours of diagnosis was obtained in patients who died, but no significant differences compared to those who did not die were observed. C-reactive protein and procalcitonin showed increased values in most patients. Conclusions: The findings of this study are related to others where it is concluded that presepsin is a good marker of sepsis with an important prognostic value and greater specificity than other traditional biomarkers.


REFERENCES

  1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538.

  2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.

  3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.

  4. Tanriover MD, Guven GS, Sen D, Unal S, Uzun O. Epidemiology and outcome of sepsis in a tertiary-care hospital in a developing country. Epidemiol Infect 2006; 134: 315-322.

  5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.

  6. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32: S495-512.

  7. Rodriguez F, Barrera L, De La Rosa G, Dennis R, Duenas C, Granados M, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. Crit Care Med 2011; 39: 1675-1682.

  8. Restrepo MI, Dueñas C, González M, Ortiz G, Granados M, Álvarez C, et al. Consenso colombiano en sepsis. Infectio 2007; 11: 46-56.

  9. Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29: 1043-1051.

  10. Hernández-Bou S, Trenchs Sainz de la Maza V, Esquivel Ojeda JN, Gené Giralt A, Luaces Cubells C. Factores predictores de contaminación ante un hemocultivo con crecimiento bacteriano en Urgencias. An Pediatr 2015; 82: 426- 432.

  11. Zhang J, Hu ZD, Song J, Shao J. Diagnostic Value of Presepsin for Sepsis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94: e2158.

  12. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013; 50: 23-36.

  13. Cho SY, Choi JH. Biomarkers of sepsis. Infect Chemother 2014; 46: 1-12.

  14. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005; 11: 234-238.

  15. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14- ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011; 17: 764-769.

  16. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 2011; 49: 937-939.

  17. Carpio R, Zapata J, Spanuth E, Hess G. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta 2015; 450: 169-175.

  18. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977-983.

  19. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.

  20. Abbott Laboratories. C-reactive protein. Illinois, Estados Unidos. 2008. Disponible: http://www.ilexmedical. com/files/PDF/CRP_ARC_CHEM.pdf. Consultado: feb 2017.

  21. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry (ed 3a). Filadelfia, Estados Unidos: WB Saun ders; 1998.

  22. Mitsubishi Chemical Europe GmbH, LSI Medience Corporation. PATHFASTTM Presepsin. 2014. Disponible: http://www.pathfast.de/images/stories/download/PF_ Folder_SEPSIS_2014.pdf. Consultado: feb 2017.

  23. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.

  24. López-Vallejo CA. Epidemiología de la sepsis en la Fundación Cardioinfantil - Instituto de Cardiología - Bogotá. Tesis para optar al título de Especialista en Medicina Interna. Bogotá D.C., Colombia: Universidad del Rosario; 2009.

  25. Julián-Jiménez A, Palomo-De Los Reyes MJ, Ortiz- Díaz-Miguel R, Pedrosa-Guerrero A, Parejo-Miguez R, Salcedo-Martínez R. Utilidad de la procalcitonina y la proteína C reactiva en el paciente con sepsis en urgencias. Emergencias 2009; 21: 23-27.

  26. Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001; 27: 211-215.

  27. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012; 18: 891-897.

  28. Pertuz M Y, González R G, Acosta M S. Uso de biomarcadores de inflamación o infección en el diagnóstico de sepsis, en unidades de cuidados intensivos de Santa Marta, Colombia. Biosalud 2016; 15: 28-36.

  29. Sánchez-González RA, Becerra-Victorio G, Grajales- Avendaño L, Canseco-Ávila LM. Frecuencia de microorganismos aislados de hemocultivos en un hospital de tercer nivel en el estado de Chiapas. Enf Inf Microbiol 2010; 30: 53-58.

  30. Tong X, Cao Y, Yu M, Han C. Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis. Ther Clin Risk Manag 2015; 11: 1027-1033.

  31. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005; 11: 101-108.

  32. Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care 2008; 12: R161.

  33. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.




2020     |     www.medigraphic.com